Michael Leviten
Plus aucun poste en cours
Profil
Michael Leviten worked as a Director-Molecular Biology at Bayhill Therapeutics, Inc. from 2005 to 2013.
He also worked as a Senior Scientist at Deltagen, Inc. Dr. Leviten received his undergraduate degree from Harvard University and his doctorate degree from the University of California San Diego.
Anciens postes connus de Michael Leviten
| Sociétés | Poste | Fin |
|---|---|---|
Bayhill Therapeutics, Inc.
 Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 26/12/2013 |
| DELTAGEN INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Michael Leviten
| Harvard University | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DELTAGEN INC. | Commercial Services |
| Entreprise privées | 1 |
|---|---|
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | Health Technology |
